Skip to main content

Week In Review: Pyrotech Closes $97 Million Series A Round For Immunomodulator Drugs

Beijing’s Pyrotech Therapeutics completed a $97 million Series A funding to develop novel small molecule drugs that modulate immune responses for autoimmune diseases. Meanwhile, Mirxes Holding closed a Series D funding round that raised $50 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.